Browse the corpus

This activity provides an in-depth review of calcitriol, a hormonally active synthetic vitamin D analog prescribed to manage hypocalcemia and renal osteodystrophy. FDA-approved indications include treating hypocalcemia in patients undergoing chronic renal dialysis, secondary hyperparathyroidism in those with chronic kidney disease not yet requiring dialysis, and hypocalcemia in patients with hypoparathyroidism or pseudohypoparathyroidism. The activity examines the mechanism of action, administration routes, and pharmacokinetics of calcitriol, along with strategies for effective monitoring to optimize therapeutic outcomes. Significant adverse events, contraindications, and clinically relevant drug-drug interactions are discussed to support safe prescribing practices. A review of calcitriol’s toxicological profile and strategies to minimize adverse effects is also included to enhance patient safety. Additionally, collaboration within the interprofessional healthcare team is emphasized to individualize treatment plans and improve patient outcomes when using calcitriol for indicated conditions. Objectives: Evaluate the mechanism of action of calcitriol. Identify the FDA-approved indications and off-label uses of calcitriol. Screen for contraindications and risks associated with calcitriol therapy. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from calcitriol therapy. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose The median lethal dose for oral administration in rats is 620 μg/kg, and the median lethal dose for intraperitoneal administration is greater than 5 mg/kg. Overdose symptoms of hypercalcemia include anorexia, nausea, vomiting, polyuria, polydipsia, and weakness.[31] Management of Overdose Treatment for calcitriol overdose includes general supportive measures. Immediate discontinuation of calcitriol and a low-calcium diet is recommended. The initial treatment for symptomatic or severe hypercalcemia typically involves hydration and intravenous bisphosphonates, such as zoledronic acid or pamidronate. For patients with renal impairment, denosumab and dialysis may be required.[31] Drugs like phosphates and corticosteroids may help induce excretion and forced diuresis in persistent, elevated calcium levels. One hypothesis involves ketoconazole or fluconazole, which inhibit CYP27B1, and can be effective in cases of calcitriol toxicity; further research is required.[32] Consult a toxicologist or poison control center for the latest recommendations.

Calcitriol is a widely prescribed agent by primary care providers, nurse practitioners, endocrinologists, dermatologists, and internists. However, therapy with the drug requires an entire interprofessional healthcare team, including clinicians, nurses, and pharmacists. While calcitriol is relatively safe, patients must be monitored for adverse effects, the most common of which is hypercalcemia. Patients may present with hypertension, renal stones, behavior alterations, and severe constipation. At each clinic visit, the healthcare provider should ask for symptoms of hypercalcemia. In some patients, regular monitoring of calcium levels may be required.[33] Endocrinologists, nephrologists, and dermatologists initiate calcitriol treatment based on clinical diagnosis. Resident physicians carry out follow-ups of the patients and therapy adjustments as indicated. Physician assistants and nurse practitioners follow the patient's response to treatment and accordingly adjust in consultation with the clinical team. Pharmacists check proper dosing and monitor drug interaction. Nurses deliver the treatment, monitor adverse effects, and support patients during treatment. For patients experiencing an overdose, emergency medicine and critical care physicians must be quick to treat acute conditions and keep the patient stable in hypercalcemia. The collaborative interprofessional efforts of clinicians, nurses, and pharmacists significantly enhance patient outcomes while minimizing the risk of adverse effects related to calcitriol therapy.